Additional Relevant Details Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than September 2034. The allowed claims cover a method of treating advanced NASH with fibrosis, a method of reducing hepatic fibrosis in advanced NASH, and a method of reducing hepatic scarring in advanced NASH using MN-001 or MN-002. The allowed claims cover oral administration, including tablets and capsules, as well as liquid dosage forms.